ArticleDiscover oncology2025
MED8 is related to tumor immunity and has predictive value in the prognosis and treatment of glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMediator complex subunit 8 (MED8) is the main regulator of RNA polymerase. Its expression is associated with a poor prognosis and tumor immune features in many tumors, but the role of MED8 in gliomas is unknown.
methodsIn this study, bioinformatics analysis was used to explore the effect of MED8 in gliomas and the correlation between MED8 and tumor immune features and the response to immunotherapy in gliomas. The expression of MED8 in cell lines was studied by qPCR.
resultsStudies show increased expression of MED8 is associated with poor prognosis in glioma. Cox regression analysis and survival analysis revealed that MED8 is an independent prognostic factor in gliomas, and patients with high expression of MED8 have a poor prognosis. Functional analysis revealed that there was a close relationship between MED8 expression and tumor immune features, and there was a correlation between MED8 expression and tumor-associated macrophages (TAMs) levels. In addition, glioma patients with low expression of MED8 were more sensitive to anti-PD-1/anti-CTLA4 immunotherapy, while patients with high expression of MED8 were more sensitive to temozolomide (TMZ).
conclusionThese results show that MED8 is a marker of prognosis and immunotherapy/chemotherapy response in glioma and a target of anti-TAMs immunotherapy for glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.